Name | Number of supported studies | Average coverage | |
---|---|---|---|
type II pneumocyte | 11 studies | 40% ± 16% | |
endothelial cell | 8 studies | 27% ± 8% | |
respiratory goblet cell | 4 studies | 28% ± 9% | |
connective tissue cell | 3 studies | 48% ± 19% |
Insufficient scRNA-seq data for expression of ALPL at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 97% | 8831.54 | 559 / 578 | 70% | 84.12 | 806 / 1155 |
brain | 84% | 1112.83 | 2216 / 2642 | 81% | 29.15 | 568 / 705 |
liver | 100% | 5658.57 | 226 / 226 | 59% | 38.28 | 240 / 406 |
kidney | 97% | 3630.11 | 86 / 89 | 59% | 69.95 | 534 / 901 |
breast | 97% | 3323.13 | 446 / 459 | 45% | 22.64 | 508 / 1118 |
thymus | 87% | 1249.94 | 567 / 653 | 49% | 17.19 | 295 / 605 |
adrenal gland | 100% | 9340.24 | 258 / 258 | 35% | 56.88 | 81 / 230 |
ovary | 21% | 200.10 | 37 / 180 | 88% | 143.31 | 379 / 430 |
spleen | 100% | 7915.76 | 241 / 241 | 0% | 0 | 0 / 0 |
prostate | 74% | 1140.76 | 181 / 245 | 26% | 8.13 | 130 / 502 |
adipose | 93% | 2835.84 | 1115 / 1204 | 0% | 0 | 0 / 0 |
heart | 91% | 1516.13 | 786 / 861 | 0% | 0 | 0 / 0 |
uterus | 49% | 546.28 | 83 / 170 | 35% | 40.30 | 160 / 459 |
peripheral blood | 81% | 54886.51 | 756 / 929 | 0% | 0 | 0 / 0 |
skin | 37% | 464.96 | 675 / 1809 | 29% | 11.51 | 139 / 472 |
bladder | 33% | 468.24 | 7 / 21 | 23% | 15.52 | 116 / 504 |
stomach | 42% | 417.94 | 149 / 359 | 12% | 5.79 | 35 / 286 |
pancreas | 22% | 161.62 | 71 / 328 | 30% | 10.85 | 53 / 178 |
esophagus | 25% | 229.12 | 368 / 1445 | 24% | 7.65 | 44 / 183 |
intestine | 40% | 510.70 | 387 / 966 | 8% | 3.22 | 43 / 527 |
lymph node | 0% | 0 | 0 / 0 | 41% | 15.99 | 12 / 29 |
tonsil | 0% | 0 | 0 / 0 | 29% | 7.41 | 13 / 45 |
blood vessel | 27% | 485.58 | 360 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 16% | 3.54 | 13 / 80 |
muscle | 1% | 4.26 | 5 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0055074 | Biological process | calcium ion homeostasis |
GO_0055062 | Biological process | phosphate ion homeostasis |
GO_0036005 | Biological process | response to macrophage colony-stimulating factor |
GO_0001649 | Biological process | osteoblast differentiation |
GO_0032868 | Biological process | response to insulin |
GO_0001958 | Biological process | endochondral ossification |
GO_0034516 | Biological process | response to vitamin B6 |
GO_0019725 | Biological process | cellular homeostasis |
GO_1904383 | Biological process | response to sodium phosphate |
GO_0140651 | Biological process | futile creatine cycle |
GO_0051384 | Biological process | response to glucocorticoid |
GO_0046677 | Biological process | response to antibiotic |
GO_0030282 | Biological process | bone mineralization |
GO_0071529 | Biological process | cementum mineralization |
GO_0016311 | Biological process | dephosphorylation |
GO_0120162 | Biological process | positive regulation of cold-induced thermogenesis |
GO_0140928 | Biological process | inhibition of non-skeletal tissue mineralization |
GO_0001501 | Biological process | skeletal system development |
GO_0042822 | Biological process | pyridoxal phosphate metabolic process |
GO_0003006 | Biological process | developmental process involved in reproduction |
GO_0071407 | Biological process | cellular response to organic cyclic compound |
GO_0033280 | Biological process | response to vitamin D |
GO_0032496 | Biological process | response to lipopolysaccharide |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0031966 | Cellular component | mitochondrial membrane |
GO_0005758 | Cellular component | mitochondrial intermembrane space |
GO_0070062 | Cellular component | extracellular exosome |
GO_0031012 | Cellular component | extracellular matrix |
GO_0098552 | Cellular component | side of membrane |
GO_0004427 | Molecular function | inorganic diphosphate phosphatase activity |
GO_0033883 | Molecular function | pyridoxal phosphatase activity |
GO_0004035 | Molecular function | alkaline phosphatase activity |
GO_0052732 | Molecular function | phosphoethanolamine phosphatase activity |
GO_0005509 | Molecular function | calcium ion binding |
GO_0016462 | Molecular function | pyrophosphatase activity |
GO_0043262 | Molecular function | ADP phosphatase activity |
GO_0050187 | Molecular function | phosphoamidase activity |
GO_0016887 | Molecular function | ATP hydrolysis activity |
Gene name | ALPL |
Protein name | alkaline phosphatase (EC 3.1.3.1) Alkaline phosphatase, tissue-nonspecific isozyme (EC 3.1.3.1) (EC 3.9.1.1) (Alkaline phosphatase liver/bone/kidney isozyme) (Phosphoamidase) (Phosphocreatine phosphatase) Alkaline phosphatase, tissue-nonspecific isozyme (AP-TNAP) (TNS-ALP) (TNSALP) (EC 3.1.3.1) (Alkaline phosphatase liver/bone/kidney isozyme) (Phosphoamidase) (Phosphocreatine phosphatase) (EC 3.9.1.1) |
Synonyms | |
Description | FUNCTION: Alkaline phosphatase that metabolizes various phosphate compounds and plays a key role in skeletal mineralization and adaptive thermogenesis . Has broad substrate specificity and can hydrolyze a considerable variety of compounds: however, only a few substrates, such as diphosphate (inorganic pyrophosphate; PPi), pyridoxal 5'-phosphate (PLP) and N-phosphocreatine are natural substrates . Plays an essential role in skeletal and dental mineralization via its ability to hydrolyze extracellular diphosphate, a potent mineralization inhibitor, to phosphate: it thereby promotes hydroxyapatite crystal formation and increases inorganic phosphate concentration . Acts in a non-redundant manner with PHOSPHO1 in skeletal mineralization: while PHOSPHO1 mediates the initiation of hydroxyapatite crystallization in the matrix vesicles (MVs), ALPL/TNAP catalyzes the spread of hydroxyapatite crystallization in the extracellular matrix (By similarity). Also promotes dephosphorylation of osteopontin (SSP1), an inhibitor of hydroxyapatite crystallization in its phosphorylated state; it is however unclear whether ALPL/TNAP mediates SSP1 dephosphorylation via a direct or indirect manner (By similarity). Catalyzes dephosphorylation of PLP to pyridoxal (PL), the transportable form of vitamin B6, in order to provide a sufficient amount of PLP in the brain, an essential cofactor for enzymes catalyzing the synthesis of diverse neurotransmitters . Additionally, also able to mediate ATP degradation in a stepwise manner to adenosine, thereby regulating the availability of ligands for purinergic receptors (By similarity). Also capable of dephosphorylating microbial products, such as lipopolysaccharides (LPS) as well as other phosphorylated small-molecules, such as poly-inosine:cytosine (poly I:C) . Acts as a key regulator of adaptive thermogenesis as part of the futile creatine cycle: localizes to the mitochondria of thermogenic fat cells and acts by mediating hydrolysis of N-phosphocreatine to initiate a futile cycle of creatine dephosphorylation and phosphorylation (By similarity). During the futile creatine cycle, creatine and N-phosphocreatine are in a futile cycle, which dissipates the high energy charge of N-phosphocreatine as heat without performing any mechanical or chemical work (By similarity). . |
Accessions | ENST00000374840.8 [P05186-1] ENST00000540617.5 [P05186-3] ENST00000374832.5 [P05186-1] G8I0M6 ENST00000374830.2 B1ANL0 P05186 ENST00000539907.5 [P05186-2] |